PROACT Xa: Patient Enrollment

If you have an On-X® Aortic Mechanical Heart Valve, you may be eligible to be enrolled in an exciting clinical study. 

The PROACT Xa Clinical Trial is studying whether a different blood thinning medication – apixaban (marketed under the brand name ELIQUIS®) – will provide the same benefit for patients with an On-X Aortic Mechanical Heart Valve compared with warfarin (marketed under the brand name COUMADIN®).

Contact us to learn more about the PROACT Xa study, your potential eligibility for the study, and/or which hospitals and institutions are participating in the study.

    Your Name*

    Phone Number*

    Your Email*

    *All Fields are Required

    By submitting your information, you agree that Artivion or its affiliates may contact you about the PROACT Xa Clinical Trial using the contact information provided, which may not be entirely secure from interception, and that you have read and agree to our Terms of Use and Privacy Policy.

    Except as otherwise noted, all trademarks are owned by Artivion, Inc. or its subsidiaries.  The On-X Aortic Valve is not currently approved by the FDA for use with apixaban or any other anticoagulation, except vitamin K antagonist. ELLIQUIS® is a registered trademark of the Bristol-Myers Squibb Company. Neither Artivion nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company. Not all products and indications are available or approved in all markets. © 2022 Artivion, Inc. All rights reserved. 

    MLENG1561.000 (2022-08)